Cargando…

Intensity of Lipid-Lowering Therapy Among Patients With Polyvascular Disease

This cohort study assesses patterns in treatment of low-density lipoprotein cholesterol using lipid-lowering therapy among patients with and without polyvascular disease.

Detalles Bibliográficos
Autores principales:	Peterson, Benjamin E., Bhatt, Deepak L., Ballantyne, Christie M., de Lemos, James A., Rosenson, Robert S., Kosiborod, Mikhail N., Cannon, Christopher P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043744/ https://www.ncbi.nlm.nih.gov/pubmed/36972054 http://dx.doi.org/10.1001/jamanetworkopen.2023.4709

Ejemplares similares

What Do US Physicians and Patients Think About Lipid‐Lowering Therapy and Goals of Treatment? Results From the GOULD Registry
por: Arnold, Suzanne V., et al.
Publicado: (2021)

Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
por: Cannon, Christopher P., et al.
Publicado: (2021)

Use of lipid‐lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2‐year results from Getting to an imprOved Understanding of Low‐Density lipoprotein cholesterol and dyslipidemia management (GOULD)
por: Shaik, Aleesha, et al.
Publicado: (2022)

Meta‐Analysis of Intensive Lipid‐Lowering Therapy in Patients With Polyvascular Disease
por: Alkhalil, Mohammad, et al.
Publicado: (2021)

Adherence to Guideline Medication Recommendations to Prevent Atherosclerotic Cardiovascular Disease Progression Among Adults With Prior Myocardial Infarction
por: Arnold, Suzanne V., et al.
Publicado: (2020)

Comprehensive Assessment of Polyvascular Atherosclerosis
por: Nakanishi, Rine, et al.
Publicado: (2018)

Systematic Review: Evaluating the Effect of Lipid-Lowering Therapy on Lipoprotein and Lipid Values
por: Rosenson, Robert S., et al.
Publicado: (2013)

Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease
por: Tmoyan, Narek A., et al.
Publicado: (2021)

Polyvascular Disease and the Incidence of Cancer in Patients with Coronary Artery Disease
por: Suzuki, Makoto, et al.
Publicado: (2022)

Associations Between Polyvascular Disease and Stroke Recurrence in Patients With Lacunar Stroke
por: Ma, Lin, et al.
Publicado: (2021)

Preclinical carotid atherosclerosis as an indicator of polyvascular disease: a narrative review
por: Poredos, Pavel, et al.
Publicado: (2021)

Prognostic Role of Polyvascular Involvement in Patients with Symptomatic Peripheral Artery Disease
por: Adam, Luise, et al.
Publicado: (2023)

Risk Factors for Polyvascular Involvement in Patients With Peripheral Artery Disease: A Mendelian Randomization Study
por: Dikilitas, Ozan, et al.
Publicado: (2020)

Polyvascular Disease in Patients Presenting with Acute Coronary Syndrome: Its Predictors and Outcomes
por: Al Thani, Hassan, et al.
Publicado: (2012)

Time‐Dependent Cardiovascular Treatment Benefit Model for Lipid‐Lowering Therapies
por: Khan, Irfan, et al.
Publicado: (2020)

Asymptomatic Polyvascular Abnormalities in Community (APAC) Study in China: Objectives, Design and Baseline Characteristics
por: Zhou, Yong, et al.
Publicado: (2013)

Prognostic significance of polyvascular disease in heart failure with preserved left ventricular ejection fraction
por: Fujisue, Koichiro, et al.
Publicado: (2019)

Correction: Asymptomatic Polyvascular Abnormalities in Community (APAC) Study in China: Objectives, Design and Baseline Characteristics
por: Zhou, Yong, et al.
Publicado: (2014)

Characterization of Polyvascular Disease in Heterozygous Familial Hypercholesterolemia: Its Association With Circulating Lipoprotein(a) Levels
por: Funabashi, Sayaka, et al.
Publicado: (2022)

Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease
por: Szarek, Michael, et al.
Publicado: (2022)

Asymptomatic polyvascular atherosclerotic disease requires a complex management strategy – case report and review of the literature
por: Jurcut, R, et al.
Publicado: (2009)

Carotid Atherosclerosis, Cerebrospinal Fluid Pressure, and Retinal Vessel Diameters: The Asymptomatic Polyvascular Abnormalities in Community Study
por: Yang, Jing Yan, et al.
Publicado: (2016)

Association of Polyvascular Disease and Elevated Interleukin-6 With Outcomes in Acute Ischemic Stroke or Transient Ischemic Attack
por: Tian, Ye, et al.
Publicado: (2021)

Representation of Women Authors in Trials of Lipid‐Lowering Therapy
por: Raghu Subramanian, Charumathi, et al.
Publicado: (2021)

Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
por: Shen, Miles, et al.
Publicado: (2022)

Study Design, Rationale, and Baseline Characteristics: Evaluation of Fenofibric Acid on Carotid Intima-Media Thickness in Patients with Type IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial
por: Davidson, Michael, et al.
Publicado: (2012)

Use of non‐LDL‐C lipid‐lowering medications in patients with type 2 diabetes
por: Arnold, Suzanne V., et al.
Publicado: (2020)

Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease
por: Jönelid, Birgitta, et al.
Publicado: (2019)

Influence of polyvascular disease on clinical outcome in patients undergoing transcatheter aortic valve implantation via transfemoral access
por: Yamawaki, Masahiro, et al.
Publicado: (2021)

Quantification of Utilization Management Barriers for Patients Initiating Therapy to Lower Lipid Levels
por: O’Neil, Adam, et al.
Publicado: (2022)

Intensive Lipid-Lowering Therapy Ameliorates Asymptomatic Intracranial Atherosclerosis
por: Miao, Huijuan, et al.
Publicado: (2019)

The prevalence of carotid plaque with different stability and its association with metabolic syndrome in China: The Asymptomatic Polyvascular Abnormalities Community study
por: Wang, Anxin, et al.
Publicado: (2016)

Circulating Ageing Neutrophils as a Marker of Asymptomatic Polyvascular Atherosclerosis in Statin-Naïve Patients without Established Cardiovascular Disease
por: Genkel, Vadim, et al.
Publicado: (2022)

SUN-149 Cardiologist vs. Endocrinologist Encounters in Patients with T2D and CVD: Potential Implications for Glucose-Lowering Therapy Use and Education
por: Gunawan, Felona, et al.
Publicado: (2019)

Elevated Serum Cystatin C and Decreased Cathepsin S/Cystatin C Ratio Are Associated with Severe Peripheral Arterial Disease and Polyvascular Involvement
por: Nagy, Előd Ernő, et al.
Publicado: (2022)

Carotid total plaque area as an independent predictor of short-term subclinical polyvascular atherosclerosis progression and major adverse cardiac and cerebrovascular events
por: Genkel, Vadim, et al.
Publicado: (2023)

Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
por: Verma, Subodh, et al.
Publicado: (2021)

Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
por: Abdalwahab, Ahmed, et al.
Publicado: (2021)

The Future of Lipid-Lowering Therapy
por: van Zwol, Willemien, et al.
Publicado: (2019)

Risk Score to Predict Need for Intensive Care in Initially Hemodynamically Stable Adults With Non–ST‐Segment–Elevation Myocardial Infarction
por: Fanaroff, Alexander C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_cl5dseth5uag733f4cjddc0bbh